Compares two surgeries to lower ovarian cancer risk in high-risk women
Tests removing the fallopian tubes first, with later ovary removal, in women with gene changes.
Plain-language title generated from the registry record
Registry title: TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention
Key facts
- Where
- Vancouver, CanadaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for women who carry a harmful BRCA1, BRCA2, RAD51C, RAD51D or BRIP1 gene change and have finished having children. It compares removing the fallopian tubes first and the ovaries later with removing both at once.
- Age
- BRCA1: 25-40 years. BRCA2: 25-45 years. RAD51C, RAD51D, BRIP1: 25-50 years.
- Sex
- Women only.
- Disease stage
- No ovarian, fallopian tube or peritoneal cancer. A past cancer outside the ovaries is allowed. At least one fallopian tube must be present.
- Earlier treatment
- Cannot have had both fallopian tubes removed before.
- Biomarker or test result
- A class 5 (definitely pathogenic) germline mutation in BRCA1, BRCA2, RAD51C, RAD51D or BRIP1.
Main reasons for not taking part
- Postmenopausal (natural or due to treatment)
- Wish for the second surgery (ovary removal) within two years after the first
- Past ovarian, fallopian tube or peritoneal cancer
- Current diagnosis or treatment for cancer
- Legally incapable
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 25 and 50 years old?
- Have you ever been told you have ovarian, fallopian tube or peritoneal cancer?
Source: NCT04294927, who can take part
Where in Canada
- Vancouver General HospitalVancouver, CanadaContact: Janice KwonTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- University Medical Center Nijmegen
- Trial code
- NCT04294927
- Record updated
- 6 April 2026
- Original description
The aim of the project is to evaluate the risk-reducing salpingectomy with delayed oophorectomy as an alternative for risk-reducing salpingo-oophorectomy in high risk women with respect to ovarian cancer incidence.Read full original descriptionShow less
TUBectomy With Delayed Oophorectomy as Alternative for Risk-reducing Salpingo-oophorectomy in High Risk Women to Assess the Safety of Prevention: TUBA-WISP II Study.
The aim of the project is to evaluate the risk-reducing salpingectomy with delayed oophorectomy as an alternative for risk-reducing salpingo-oophorectomy in high risk women with respect to ovarian cancer incidence.
Inclusion: Women with a class 5 (definitely pathogenic) BRCA1, BRCA2, RAD51C, RAD51D or BRIP1 germline mutation in one of the participating centers; Age at inclusion; BRCA1: 25-40 years; BRCA2: 25-45 years; RAD51C, RAD51D, BRIP1: 25-50 years; Childbearing completed; Presence of at least one fallopian tube; Participants may have a personal history of non-ovarian malignancy; Informed consent must be obtained and documented according to national and local regulatory requirements and the local rules followed in the institution.
Exclusion: Prior bilateral salpingectomy; A personal history of ovarian, fallopian tube or peritoneal cancer; Current diagnosis or treatment for malignant disease; Postmenopausal status (natural menopause or due to treatment); Wish for second stage RRO within two years after RRS; Legally incapable.